Smith & Nephew (LON:SN) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why

Smith & Nephew plc (LON:SN)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,041.71 ($13.98) and traded as high as GBX 1,088.50 ($14.61). Smith & Nephew shares last traded at GBX 1,077.50 ($14.46), with a volume of 1,325,064 shares.

Smith & Nephew Stock Down 0.5%

The business has a 50-day simple moving average of GBX 1,051.38 and a two-hundred day simple moving average of GBX 1,041.71. The company has a market cap of £11.81 billion, a price-to-earnings ratio of 38.79, a PEG ratio of 0.46 and a beta of 0.62. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22.

Insiders Place Their Bets

In other Smith & Nephew news, insider Sybella Stanley acquired 3,810 shares of the company’s stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average cost of GBX 1,101 ($14.77) per share, for a total transaction of £41,948.10 ($56,291.06). Also, insider Jeremy (Jez) Maiden acquired 1,855 shares of the company’s stock in a transaction dated Thursday, May 1st. The stock was acquired at an average price of GBX 1,070 ($14.36) per share, for a total transaction of £19,848.50 ($26,635.13). Insiders own 0.19% of the company’s stock.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.